Jeffrey A. Sosman, MD Professor of Medicine Ingram Chair for Cancer Research Director, Melanoma Program Co-Leader VICC Signal Transduction & Cell Proliferation Research Program Division of Hematology/Oncology Vanderbilt University School of Medicine Nashville, TN
AMA PRA Category 1 Credit™ Medium
Mobile + Online on Univadis
Metastatic melanoma is a devastating cancer that has had very few effective treatment options until very recently. Treating patients can be challenging because of the modest efficacy of conventional regimens and the constantly evolving understanding of how to optimize therapies. Because the understanding of the underlying biology affecting therapy continues to evolve, and because investigations of new and emerging treatment regimens are ongoing, it can be challenging for oncologists to determine the most appropriate therapeutic options for their patients.
New directions for the treatment of metastatic melanoma include targeted therapies that capitalize on the growing understanding of the genetic and molecular features of the disease. In addition, care of patients with advanced disease can benefit from improved assessment of patient response and better communication between health care clinicians. This activity outlines the evolving understanding of novel therapies and new treatment approaches for patients with metastatic melanoma, with the ultimate goal of improving patient outcomes.
. Target Audience
This educational activity is designed to meet the needs of oncologists, oncology nurses, and other health care professionals who treat patients with melanoma.
Upon completion of this educational activity, the participant should be able to:
Describe the evolving concept of individualizing therapy for patients with advanced and metastatic melanoma.
Explain the application of new and emerging therapeutic options for the treatment of advanced and metastatic melanoma.
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity.
Dr. Sosman discloses the following relationships with the commercial interests:
Genentech, Honorarium, Advisor
Amgen, Honorarium, Advisor
BMS, Research, Principal Investigator
Novartis, Research, Principal Investigator
Perelman School of Medicine at the University of Pennsylvania Office of CME:
Zalman S. Agus, MD, reported no relevant financial relationships.
Mila Kostic reported no relevant financial relationships.
Michael Schoen, PhD, reported no relevant financial relationships.
Kathleen Hines, MCM Education editorial director, reported no relevant financial relationships.
Investigational and/or Off-Label Use of Commercial Products and Devices: The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports his presentation will not contain reference to investigational and/or off-label uses of agents. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and MCM Education. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.
The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: January 31, 2014
Last review date: January 31, 2014
Expiration date: January 31, 2015 Commercial Support Statements
Supported by an independent educational grant from Bristol-Myers Squibb.
* Link to and Log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 75%
* You are allowed a total of 3 attempts
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
© 2014, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the Perelman School of Medicine at the University of Pennsylvania, or Bristol-Myers Squibb. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.